ADA 2026 Closes in New Orleans After Four Days: Retatrutide, CagriSema, Foundayo, Survodutide, Petrelintide, Elecoglipron, Mazdutide, and the New Standards of Care
The 86th ADA Scientific Sessions wrapped Monday June 8 after presenting Phase 3 retatrutide TRIUMPH-1/TRANSCEND-T2D-1, CagriSema REIMAGINE 1/2/3, Foundayo ACHIEVE 1-5, survodutide SYNCHRONIZE-1, petrelintide ZUPREME-1, enicepatide CT388-103, elecoglipron VISTA/SOLSTICE, mazdutide GLORY-2/DREAMS-3, zenagamtide Phase 2, plus the inaugural ADA Standards of Care in Overweight and Obesity. The next inflection points: the July 23-24 PCAC peptide-compounding meeting, August 28 ITM-11 PDUFA in NETs, and the Foundayo T2D filing in Q2.